ArticleInternational journal of clinical oncology2018
Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.
Article in International journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis.International journal of clinical oncology · 2019Pooled it
- Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer.Translational lung cancer research · 2026Article
- Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma.Frontiers in oncology · 2025Article
- CT-based nomogram for predicting EGFR mutation status in ground-glass nodules of lung adenocarcinoma.Frontiers in immunology · 2025Article
- V7 ENB-guided thoracoscopic sublobectomy for stage IA synchronous multiple primary lung cancer.Thoracic cancer · 2022Article
- Radiological classification, gene-mutation status, and surgical prognosis of synchronous multiple primary lung cancer.European radiology · 2022Article
- Multiple instance learning for lung pathophysiological findings detection using CT scans.Medical & biological engineering & computing · 2022Article
- Review
- Towards Machine Learning-Aided Lung Cancer Clinical Routines: Approaches and Open Challenges.Journal of personalized medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyse the differences in computed tomography (CT) features between patients with lung adenocarcinoma who have epidermal growth factor receptor (EGFR) mutations and those who have wild-type EGFR.
methodsPatients with lung adenocarcinoma (n = 156) were enrolled from October 2013 to March 2016, including 56 patients with wild-type EGFR and 100 patients with EGFR mutations. Two independent radiologists evaluated patient characteristics and imaging features. Chi-squared test, Fisher's exact test or ANOVA was applied to discriminate clinical and CT characteristics between the genotypes. A prediction tool for EGFR mutation was devised from principal component analysis.
resultsThe proportion of females and non-smokers in the exon 19 deletion and exon 21 missense groups was higher than in the wild-type group (P < 0.01). Severe emphysema was higher in the wild-type group than in the exon 19 deletion group (P < 0.01). The maximum diameter in the mediastinal window (MaxD
conclusionAs well as gender, smoking history and GGO, adenocarcinomas with EGFR mutation were significantly associated with emphysema, TDR, and the diameter in the mediastinal window. As exon 19 deletion and 21 missense mutations might be predicted by those features, the scoring system might be valuable for clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.